Sanofi Delves Further into Protein Degrader Therapies with US$2.33 B Kymera Deal
By Ashish Tripathi & Michelle Liu
Pharma Deals Review: Vol 2020 Issue 9 (Table of Contents)
Published: 8 Sep-2020
DOI: 10.3833/pdr.v2020.i9.2560 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Continuing its interest in targeted protein degradation space, Sanofi has entered into a multi-programme strategic collaboration with Kymera Therapeutics to develop and commercialise IRAK4 degraders in inflammation and immunology indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS